Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon?
Author:
Publisher
Informa UK Limited
Subject
Immunology,Immunology and Allergy
Reference110 articles.
1. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
2. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis
3. Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis
4. Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
5. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Immune checkpoint expression as prognostic biomarker candidates in non‐small cell lung carcinoma patients;Journal of Surgical Oncology;2024-07-07
2. Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours;Cancer Immunology, Immunotherapy;2024-03-30
3. Advancements in NSCLC;American Journal of Clinical Oncology;2024-02-20
4. Splicing factor proline- and glutamine-rich regulates cytotoxic T lymphocytes-mediated cytotoxicity on non-small cell lung cancer by directly binding to PD-L1 3’UTR;Medicine;2023-11-10
5. What to do after immune-checkpoint inhibitors failure in advanced non-small cell lung cancer: an expert opinion and review;Expert Review of Respiratory Medicine;2023-09-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3